A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Key claim: A Phase 2 trial is evaluating whether olutasidenib combined with a hypomethylating agent is safe and effective in patients with IDH1-mutated higher-risk MDS, CMML, or advanced MPN.
Abstract
To learn if olutasidenib, when combined with a drug called a hypomethylating agent (HMA) can help to control MDS, CMML, and/or MPN. The safety of the drug combination will also be studied.
Why this matters
IDH1 mutations occur in a small but molecularly defined subset across CMML, MDS/MPN overlap, and advanced/transformed PMF, and dedicated subtype-specific evidence for IDH1-directed combinations outside AML is lacking. This Phase 2 trial is the first prospective test of olutasidenib+HMA in active disease (not just post-transplant maintenance) across these subtypes, potentially establishing a genotype-directed standard for IDH1-mutated higher-risk MDS/CMML/advanced MPN where current options are largely extrapolated from AML or MDS.